Chris Kim - 30 Apr 2025 Form 3 Insider Report for Liminatus Pharma, Inc. (LIMN)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: LIMN
Reported as of: 30 Apr 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 30 Apr 2025, 19:15:46 UTC
Source filing: View source filing
Reporting owner signature: /s/ Chris Kim

Key filing fact

Chris Kim filed Form 3 for Liminatus Pharma, Inc. (LIMN) on 30 Apr 2025.

Key facts

This page summarizes Chris Kim's Form 3 filing for Liminatus Pharma, Inc. (LIMN).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 Apr 2025, 19:15.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LIMN holding

Common Stock, par value $0.0001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,169,406
Date: 30 Apr 2025
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of shares of Common Stock of Liminatus Pharma, Inc. held of record by Valetudo Therapeutics LLC. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.